This application seeks renewed CCSG funding for the University of Virginia (UVA) Cancer Center, a matrix cancer center that brings together 132 Members from 26 Departments in the Schools of Medicine, Nursing, and Engineering, and in the College of Arts and Sciences. The UVA Cancer Center receives $25.96M from NCI, $32.65M from other peer-reviewed sources, and $4.36M from non-peer-reviewed sources, for a total of $62.97M in overall funding. Through faculty recruitment and robust infrastructure development, the UVA Cancer Center has continued to build on its exceptional basic science foundations and has greatly enhanced its ability to accelerate clinical and translational cancer focused research. Since the last renewal, over 50 new faculty have been recruited, including twenty-four clinical investigators and/or physician-scientists and twenty- six laboratory scientists, bioengineers, population, and computational biologists. The Cancer Center has five Programs: Chemical and Structural Biology (CSB), Molecular Genetics and Epigenetics (GEN), Cancer Cell Signaling (SIG), Immunology/Immunotherapy (IMM), and Women's Oncology (WON). This application requests support for seven Shared Resources: Advanced Microscopy Facility (AMF), Animal Models of Disease Core (AMDC), Biomolecular Analysis Facility (BAF), Bioinformatics Core (BIC), Biorepository and Tissue Research Facility (BTRF), Biostatistics Shared Resource (BSR), and Flow Cytometry Core (FCC). In addition, we request support for Clinical Protocol and Data Management (CPDM) infrastructure and a Protocol Review and Monitoring System (PRMS). A completely transformed infrastructure for translational and clinical research facilitates investigations using human tissues and the implementation of clinical trials. Substantial new initiatives have been launched to reach underserved populations in Appalachia. This renewal application describes continued outstanding basic cancer research, enhanced cancer focus, and greatly strengthened clinical research leadership and infrastructure.

Public Health Relevance

The UVA Cancer Center's dual mission is to eliminate the threat of cancer, with skilled, compassionate care for the patients of today and with research and education for the patients of the future. Cancer Center Members draw on the deep resources of the University of Virginia to identify, analyze, and validate some of the most significant targets for cancer therapy, diagnosis and prevention, and to speed their translation to clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-28
Application #
9626860
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
1997-09-16
Project End
2022-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
28
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8

Showing the most recent 10 out of 539 publications